Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Nykode Therapeutics ASA has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 5 distinct examiners and 4 distinct art units. This spread indicates that the company is pursuing multiple distinct biotechnological innovations across several specialized USPTO groups. The use of 5 distinct examiners for 5 pending office actions ensures that each application receives an independent technical review.
The busiest examiner for the portfolio is YU, DELPHINUS DOU YI, who manages 1 pending office action. Since each of the 5 distinct examiners is responsible for exactly 1 pending matter, the workload is evenly distributed. The presence of 4 distinct art units suggests that the company's applications cover a variety of technical sub-specialties within the pharmaceutical sector. Practitioners must manage 5 separate prosecution tracks simultaneously.
This decentralized structure requires a flexible prosecution strategy that can adapt to the varying requirements of 5 different individuals and 4 distinct art units. The company's success is not dependent on any single examiner, as YU, DELPHINUS DOU YI only oversees 1 of the 5 active matters. This distribution reduces the risk that a single examiner's specific tendencies will affect the entire portfolio of 5 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560272 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | KAUFMAN, CLAIRE M | — |
| 17997407 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | GILL, RACHEL B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560272 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | KAUFMAN, CLAIRE M | — |
| 18558492 | IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES | CHEN, STACY BROWN | — |
| 18552383 | THERAPEUTIC COMBINATION FOR TREATING CANCER | METCALF, MATTHEW CURRAN | — |
| 17997407 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | GILL, RACHEL B | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1636 | 1 |
| 1672 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560279 | CO-EXPRESSION OF CONSTRUCTS AND IMMUNOSTIMULATORY COMPOUNDS | YU, DELPHINUS DOU YI | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18560272 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | KAUFMAN, CLAIRE M | 1674 | §102§103§112Other | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18558492 | IMMUNOGENIC CONSTRUCTS AND VACCINES FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES | CHEN, STACY BROWN | 1672 | §103§112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18552383 | THERAPEUTIC COMBINATION FOR TREATING CANCER | METCALF, MATTHEW CURRAN | 1674 | §102§103DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 17997407 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | GILL, RACHEL B | 1671 | §103§112Other | Non-Final OA | — | Pending | Oct 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNykode Therapeutics ASA has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Delphinus Dou Yi Yu has the most, with 1 of Nykode Therapeutics ASA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
